Diarrhea-predominant Irritable Bowel Syndrome-like Symptoms in Patients With Quiescent Crohn’s Disease: Comprehensive Analysis of Clinical Features and Intestinal Environment Including the Gut Microbiome, Organic Acids, and Intestinal Permeability

• Published in: Journal of neurogastroenterology and motility Vol. 29; no. 1; pp. 102 - 112
• Main Authors: Toshihiko Tomita, Hirokazu Fukui, Daisuke Morishita, Ayako Maeda, Yutaka Makizaki, Yoshiki Tanaka, Hiroshi Ohno, Tadayuki Oshima, Hiroto Miwa
• Format: Journal Article
• Language: Korean
• Published: 대한소화기기능성질환·운동학회 2023
• Subjects: Anxiety; Crohn disease; Gastrointestinal microbiome; Inflammation; Irritable bowel syndrome
• ISSN: 2093-0879; 2093-0887

Background/Aims
Diarrhea-predominant irritable bowel syndrome (IBS-D)-like symptoms frequently occur in patients with quiescent Crohn’s disease (CD). To investigate the factors underlying IBS-D-like symptoms in patients with quiescent CD, we performed a comprehensive analysis of the clinical features and intestinal environment in those patients.
Methods
We performed a prospective observational study of 27 patients with quiescent CD (CD activity index [CDAI] ≤ 150; C-reactive protein ≤ 0.3 mg/dL). The presence and severity of IBS-D-like symptoms, health-related quality of life, disease-specific quality of life, and status of depression and anxiety were evaluated. The level of intestinal permeability, fecal calprotectin and organic acids and the profiles of gut microbiome were analyzed.
Results
Twelve of the 27 patients with quiescent CD (44.4%) had IBS-like symptoms, and these patients showed a significantly higher CDAI, IBS severity index and anxiety score than those without. The inflammatory bowel disease questionnaire score was significantly lower in the patients with IBS-D-like symptoms. There were no significant differences in small intestinal/colonic permeability or the levels of organic acids between the patients with and without IBS-D-like symptoms. Fusicatenibacter was significantly less abundant in the patients with IBS-D-like symptoms whereas their fecal calprotectin level was significantly higher (384.8 ± 310.6 mg/kg) than in patients without (161.0 ± 251.0 mg/kg). The receiver operating characteristic curve constructed to predict IBS-D-like symptoms in patients with quiescent CD using the fecal calprotectin level (cutoff, 125 mg/kg) showed a sensitivity and specificity of 73.3% and 91.7%, respectively.
Conclusion
Minimal inflammation is closely associated with the development of IBS-D-like symptoms in patients with quiescent CD.
(J Neurogastroenterol Motil 2023;29:102-112)